EPS Growth overview of Celgene Corporation (NASDAQ:CELG)

39
earning reaction history, nasdaq, nyse

Celgene Corporation (NASDAQ:CELG) belonging to the Medical sector has declined -0.91% and closed its last trading session at $116.56.

The company reported its EPS on 10/27/2016. Currently, the stock has a 1 Year Price Target of $138.04.

The consensus recommendation, according to Zacks Investment research, is 1.24. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.33 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.33 and 1.35 respectively.

Celgene Corporation on 10/27/2016 reported its EPS as $1.58 with the analysts projecting the EPS of the stock as $1.48. The company beat the analyst EPS Estimate with the difference of $0.1. This shows a surprise factor of 6.8%.

Many analysts have provided their estimated foresights on Celgene Corporation Earnings, with 25 analysts believing the company would generate an Average Estimate of $1.58. Whereas they predicted High and Low Earnings Estimate as $1.66 and $1.49 respectively. While in the same Quarter Previous year, the Actual EPS was $1.18.

Analysts are also projecting an Average Revenue Estimate for Celgene Corporation as $3.03 Billion in the Current Quarter. This estimate is provided by 21 analysts. The High Revenue estimate is predicted as 3.13 Billion, while the Low Revenue Estimate prediction stands at 2.94 Billion. The company’s last year sales total was 2.56 Billion.

For the Current Quarter, the growth estimate for Celgene Corporation is 33.9%, while for the Next Quarter the stock growth estimate is 22.7%. In the past 5 years, the stock showed growth of 24.64% per annum. While for the next 5 years, the growth estimate is 22.57%.

The Company got Downgrade by Standpoint Research on 9-Nov-16 from Buy to Hold.

Insider Trades for Celgene Corporation show that the latest trade was made on 9 Nov 2016 where Pehl (Michael F), the Officer completed a transaction type “Buy” in which 1876 shares were traded at a price of $59.24.

10 Insider Sales transactions were made totaling 214611 shares traded.

24 analysts projected Price Targets for Celgene Corporation. The analysts believe that the company stock price could grow as high as $162. The Low Price target projection by analysts is $92 and the Mean Price Target is $138.04.

Celgene Corporation (NASDAQ:CELG) has the market capitalization of $91.31 Billion. The company rocked its 52-Week High of $127 on Nov 9, 2016 and touched its 52-Week Low of $93.05 on Feb 3, 2016. The stock has Return on Assets (ROA) of 8 percent. Return on Equity (ROE) stands at 38.4% and Return on Investment (ROI) of 8.9 percent.

The stock is currently showing YTD performance of -2.67 Percent. The company has Beta Value of 1.75 and ATR value of 3.32. The Weekly and Monthly Volatility stands at 2.34% and 2.92%.

Company Profile:

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.